MAY 12, 2016 12:00 PM PDT

Precision Medicine 2.0: Impact Requires Data, Collaboration, Champions

2 8 185

  • Chief Medical Officer, DNAnexus
      As Chief Medical Officer, David is responsible for driving clinical impact, working closely with management and engineering teams, and with external partners and collaborators. Most recently at Theravance Biopharma, David focused on strategy and business development, and led a product team. Prior, he was a management consultant at the Boston Consulting Group, and was an early member of the Department of Experimental Medicine at Merck Research Labs. He was also a founding advisor of Sage Bionetworks, and a co-founder of the MGH/MIT Center for Assessment Technology and Continuous Health (CATCH). David received his M.D. from the Harvard-MIT Division of Health, Science, and Technology at Harvard Medical School, and his Ph.D. from the Department of Biology at MIT. He trained in internal medicine and endocrinology at the Massachusetts General Hospital, and conducted his post-doctoral research in Doug Melton's lab at the Harvard Stem Cell Institute.


    The extravagant expectations around emerging technologies often gives way to a sense of disillusionment when the lofty expectations are not fulfilled. For genomics and precision precision to escape this cycle, it will be essentially to demonstrate palpable utility, tangible impact. We'll be there when sequencing is embraced not because it’s interesting or edgy, but because it’s so obviously useful that once you’ve seen the benefits you can’t imagine not availing yourself of it.  Achieving impact will require data, collaboration, and champions.

    Learning Objectives:

    • Recognize the cycle in emerging technologies of extravagant expectation followed by disappointment and disillusionment
    • Review examples where precision medicine is impacting patients today

    Show Resources
    Loading Comments...